MGMT and central nervous system cancer: For example, in Grade II and III gliomas, survival outcomes vary significantly on the basis of the interplay between TERTp mutations, MGMT methylation, IDH mutation, and 1p/19q codeletion.121 Notably, patients with IDH mutant gliomas and concurrent TERTp mutations have poorer prognoses than those with IDH mutations alone, underscoring the complex molecular interactions governing glioma progression.